Amniotic Fluid Beta-2-Microglobulin in Normal and Complicated Pregnancies

1982 ◽  
Vol 13 (3) ◽  
pp. 129-134 ◽  
Author(s):  
J. Puolakka ◽  
P. Ylöstalo ◽  
R. Tuimala ◽  
J. Haapalahti ◽  
Pentti A. Järvinen
Keyword(s):  
Amniotic Fluid ◽  
Beta 2 ◽  
Beta 2 Microglobulin

scholarly journals Study of Soluble HLA-G in Congenital Human Cytomegalovirus Infection

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Roberta Rizzo ◽  
Liliana Gabrielli ◽  
Daria Bortolotti ◽  
Valentina Gentili ◽  
Giulia Piccirilli ◽  
...  
Keyword(s):  
Amniotic Fluid ◽  
Pregnant Women ◽  
Human Cytomegalovirus ◽  
Hcmv Infection ◽  
Human Leukocyte ◽  
Maternal Blood ◽  
Maternal Serum ◽  
Hcmv Disease ◽  
Beta 2 ◽  
Beta 2 Microglobulin

Human leukocyte antigen-G (HLA-G) is a nonclassical HLA class I antigen that is expressed during pregnancy contributing to maternal-fetal tolerance. HLA-G can be expressed as membrane-bound and soluble forms. HLA-G expression increases strongly during viral infections such as congenital human cytomegalovirus (HCMV) infections, with functional consequences in immunoregulation. In this work we investigated the expression of soluble (s)HLA-G and beta-2 microglobulin (component of HLA) molecules in correlation with the risk of transmission and severity of congenital HCMV infection. We analyzed 182 blood samples from 130 pregnant women and 52 nonpregnant women and 56 amniotic fluid samples from women experiencing primary HCMV infection. The median levels of sHLA-G in maternal serum of women with primary HCMV infection were higher in comparison with nonprimary and uninfected pregnant women (p<0.001). AF from HCMV symptomatic fetuses presented higher sHLA-G levels in comparison with infected asymptomatic fetuses (p<0.001), presence of HLA-G free-heavy chain, and a concentration gradient from amniotic fluid to maternal blood. No significant statistical difference of beta-2 microglobulin median levels was observed between all different groups. Our results suggest the determination of sHLA-G molecules in both maternal blood and amniotic fluid as a promising biomarker of diagnosis of maternal HCMV primary infection and fetal HCMV disease.

scholarly journals Prenatal Megacystis – Is Prediction of Outcome and Renal Function Possible?

2017 ◽  
Vol 39 (04) ◽  
pp. 407-412 ◽  
Author(s):  
Regina Tschannen ◽  
Rita Gobet ◽  
Josef Wisser
Keyword(s):  
Renal Function ◽  
Amniotic Fluid ◽  
Gestational Age ◽  
Fluid Volume ◽  
Amniotic Fluid Volume ◽  
Age Related ◽  
Age Dependent ◽  
Fetal Urine ◽  
Beta 2 ◽  
Beta 2 Microglobulin

Abstract Objective To assess prenatal prognostic criteria for fetuses with megacystis in order to counsel parents. Methods In a retrospective observational study at a single tertiary referral center, we assessed the clinical course of 53 fetuses with megacystis cared for at the Department of Obstetrics of the University Hospital Zurich between 1995 and 2008 and followed them up for 2 to 12 years. We determined fetal karyotype, amniotic fluid volume and fetal urinary biochemistry as prenatal prognostic factors. The renal function of survivors was grouped according to age-related creatinine values. Using logistic regression analysis, gestational age-dependent discrimination curves and corresponding ROC curves for fetal urine, beta-2 microglobulin, osmolarity and chloride were calculated. Results 43 out of 53 fetuses underwent vesicocentesis, and spontaneous remission occurred in 3 fetuses. 15 fetuses survived, termination of pregnancy was requested in 23 cases, and 12 neonatal and 3 intrauterine deaths were observed. Reduced amniotic fluid volume showed a significant (p = 0.0027) increase of impaired renal function or perinatal death. Discrimination between survivors and non-survivors was complete for fetal urine beta-2 microglobulin with an area under the curve (AUC) of 1.0. For fetal urine osmolarity and fetal urinary chloride, the AUC was 0.81 and 0.76, respectively. Conclusion The assessment of prognosis for fetal megacystis should include fetal k aryotyping, determination of amniotic fluid and assessment of fetal urine biochemistry. Gestational age-dependent regression lines disclose clinically relevant discrimination and can be used as selection criteria for fetal interventions and parental counselling.

Serial Quantification of Urinary Protein Biomarkers to Predict Drug-induced Acute Kidney Injury

2019 ◽  
Vol 20 (8) ◽  
pp. 656-664 ◽  
Author(s):  
Yi Da ◽  
K. Akalya ◽  
Tanusya Murali ◽  
Anantharaman Vathsala ◽  
Chuen-Seng Tan ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Cystatin C ◽  
Calcineurin Inhibitors ◽  
Kidney Injury ◽  
Tubular Dysfunction ◽  
Renal Tubular Dysfunction ◽  
Protein Biomarkers ◽  
Drug Induced ◽  
Beta 2 ◽  
Beta 2 Microglobulin

Background: : Drug-induced Acute Kidney Injury (AKI) develops in 10-15% of patients who receive nephrotoxic medications. Urinary biomarkers of renal tubular dysfunction may detect nephrotoxicity early and predict AKI. Methods:: We prospectively studied patients who received aminoglycosides, vancomycin, amphotericin, or calcineurin inhibitors, and collected their serial urine while on therapy. Patients who developed drug-induced AKI (fulfilling KDIGO criteria) were matched with non-AKI controls in a 1:2 ratio. Their urine samples were batch-analyzed at time-intervals leading up to AKI onset; the latter benchmarked against the final day of nephrotoxic therapy in non- AKI controls. Biomarkers examined include clusterin, beta-2-microglobulin, KIM1, MCP1, cystatin-C, trefoil-factor- 3, NGAL, interleukin-18, GST-Pi, calbindin, and osteopontin; biomarkers were normalized with corresponding urine creatinine. Results:: Nine of 84 (11%) patients developed drug-induced AKI. Biomarkers from 7 AKI cases with pre-AKI samples were compared with those from 14 non-AKI controls. Corresponding mean ages were 55(±17) and 52(±16) years; baseline eGFR were 99(±21) and 101(±24) mL/min/1.73m2 (all p=NS). Most biomarker levels peaked before the onset of AKI. Median levels of 5 biomarkers were significantly higher in AKI cases than controls at 1-3 days before AKI onset (all µg/mmol): clusterin [58(8-411) versus 7(3-17)], beta-2-microglobulin [1632(913-3823) versus 253(61-791)], KIM1 [0.16(0.13-0.76) versus 0.07(0.05-0.15)], MCP1 [0.40(0.16-1.90) versus 0.07(0.04-0.17)], and cystatin-C [33(27-2990) versus 11(7-19)], all p<0.05; their AUROC for AKI prediction were >0.80 (confidence intervals >0.50), with average accuracy highest for clusterin (86%), followed by beta-2-microglobulin, cystatin-C, MCP1, and KIM1 (57%) after cross-validation. Conclusion: : Serial surveillance of these biomarkers could improve the lead time for nephrotoxicity detection by days.

Theiler's virus infection of beta 2-microglobulin-deficient mice.

1993 ◽  
Vol 67 (1) ◽  
pp. 589-592 ◽  
Author(s):  
L Fiette ◽  
C Aubert ◽  
M Brahic ◽  
C P Rossi
Keyword(s):  
Virus Infection ◽  
Theiler's Virus ◽  
Beta 2 ◽  
Beta 2 Microglobulin ◽  
Deficient Mice

Time-resolved fluoroimmunoassay of beta 2-microglobulin in serum and cerebrospinal fluid

1993 ◽  
Vol 39 (3) ◽  
pp. 552-553 ◽  
Author(s):  
D Meillet ◽  
L Bélec ◽  
E Schuller ◽  
J Delattre
Keyword(s):  
Cerebrospinal Fluid ◽  
Time Resolved ◽  
Beta 2 ◽  
Beta 2 Microglobulin
Sign in / Sign up

Export Citation Format

Share Document